Skip to main content
BJDX
NASDAQ Industrial Applications And Services

Bluejay Diagnostics Completes SYMON-II Enrollment, Reports $9.6M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.03
Mkt Cap
$1.086M
52W Low
$0.83
52W High
$16.68
52W Position info
24% above low
Off High info
94% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

BJDX sits 24% above its 52-week low of $0.83 on light trading volume (0.1× avg).

Summary

Bluejay Diagnostics reported Q2 2026 results, highlighting completion of SYMON-II enrollment, a manufacturing contract, and a strengthened cash position of $9.6 million.


Key Events · Earnings and Guidance · BJDX

  • SYMON-II Enrollment Complete

    The pivotal study reached its targeted enrollment of 750 hospital patients, supporting the planned FDA 510(k) submission.

  • Manufacturing Contract Signed

    A US manufacturing contract was signed to mitigate supply-chain risk ahead of commercialization.

  • Cash Position Strengthened

    The quarter ended with approximately $9.6 million in cash, up from $5.2 million at year-end 2025.

  • Runway Extended to Q2 2027

    Current cash resources are estimated to fund operations through the second quarter of 2027.


Analysis · BJDX · Industrial Applications And Services

Completing enrollment of 750 patients in the pivotal SYMON-II study marks a key step toward FDA 510(k) submission for the Symphony IL-6 sepsis test. A US manufacturing contract was also signed, and the quarter ended with $9.6 million in cash, extending the runway to Q2 2027. These updates reduce near-term financing risk and advance the regulatory timeline, though going concern and Nasdaq delisting risks remain.

How filings like this one have moved

In the 30 days to Aug 22, 2026, 29.1% of the 2927 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BJDX was trading at $1.03 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.83 to $16.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BJDX - Latest Insights

BJDX
Aug 13, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.05
Real-time Price: $0.9109 info
Change: -$0.1391 (-13%) info
Market Cap: $4.07M info
BJDX
Aug 12, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.9109 info
Change: -$0.1391 (-13%) info
Market Cap: $4.07M info
BJDX
Jul 22, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $0.9109 info
Change: -$0.2291 (-20%) info
Market Cap: $4.07M info
BJDX
Jul 21, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.17
Real-time Price: $0.9109 info
Change: -$0.2591 (-22%) info
Market Cap: $4.07M info
BJDX
Jun 26, 2026, 4:44 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $2.98
Real-time Price: $0.9109 info
Change: -$2.07 (-69%) info
Market Cap: $4.07M info